Login to Your Account

DOV Licenses Bicifadine To XTL In $130M Deal; Refocuses Pipeline

By Jennifer Boggs

Wednesday, January 17, 2007
Hoping to leave the struggles of 2006 behind, DOV Pharmaceuticals Inc. is continuing to refocus its clinical pipeline. To that end, the Somerset, N.J.-based firm licensed rights to its late-stage pain drug, bicifadine, to XTL Biopharmaceuticals Ltd. in a deal potentially worth more than $130 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription